GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 58.61B |
| Revenue (ttm) | 31.53B |
| Net Income (ttm) | 3.15B |
| Shares Out | 4.05B |
| EPS (ttm) | 0.76 |
| PE Ratio | 19.03 |
| Forward PE | 8.44 |
| Dividend | 0.61 (4.21%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 7,904,168 |
| Average Volume | 12,749,710 |
| Open | 1,450.00 |
| Previous Close | 1,463.00 |
| Day's Range | 1,447.00 - 1,478.50 |
| 52-Week Range | 1,242.50 - 1,823.50 |
| Beta | 0.30 |
| RSI | 56.45 |
| Earnings Date | Apr 28, 2025 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine product... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -...
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
GSK plc (NYSE:GSK) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels -...
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vacci...
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
On Wednesday, British multinational pharmaceutical GSK Plc (NYSE: GSK) reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. ...
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts ...
GSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate Tariffs
GSK stock jumped early Wednesday after the drugmaker reported adjusted earnings of $1.20 per share on $10.06 billion in first-quarter sales.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2207830688-9a12881aeb9749ae9aafb96f539747c0.jpg)
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
U.S.-listed shares of GSK are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the Trump...
GSK posts Q1 beat thanks to Specialty Medicines
GSK turns to AI to offset potential US tariff hit
Drugmaker says it can harness technology and change supply chain to guard against possible new levies
GSK reports Q1 results
Earnings Scheduled For April 30, 2025
Companies Reporting Before The Bell • Wabash National (NYSE: WNC) is expected to report quarterly loss at $0.28 per share on revenue of $409.85 million. • Timken (NYSE: TKR) is projected to report q...
Drugs giant GSK ‘well positioned’ to absorb potential US tariffs
It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality medicines.
GSK Sales, Profit Rise on Boost from Cancer Drugs
The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the year prior.
British drugmaker GSK says 'well positioned' to absorb tariff hit
British drugmaker GSK said on Wednesday it was "well positioned" to respond to any potential financial impact from sector-specific tariffs if they were implemented and it had identified options within...
FTSE 100 Live 30 April: Barclays and GSK post updates, index on best run for eight years
GSK Q1 2025 Earnings Preview
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
UK approves combination therapies of GSK's blood cancer drug Blenrep
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at ...
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., Apri...
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Arexvy--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices.
GSK’s meningococcal vaccine gets positive recommendation from ACIP
GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK's 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices.